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Two potent inflammatory mediators, interleukin 1 (IL-l) and tumor necrosis factor (TNF) as well as lipopolysa~ha~de (LPS) increased group 
II phospholipase 4 (PL4) mRNA levels, which resulted in enhanced secretion of the PL4 enzyme from rat smooth muscle cells. CAMP-elevating 
agents also stimulated the release of PL4 and increased the mRNA, but IL-I, TNF and LPS did not affect CAMP levels. Furthermore, the effects 
of TNF and CAMP-elevating agents were not additive but synergistic. Therefore, we concluded that the level of rat group II PL4 mRNA is con- 
trolled at least by two distinct mechanisms, one involves CAMP and the other is mediated by TNF, IL-l and LPS. This study also suggests important 
roles of group II PLA, in pathogenesis of vascular inflammation. 
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1. INTRODUCTION 
In several inflammatory regions, levels of ex- 
tracellular PLA2 activity are described to be elevated, 
which has been thought to play an important role in 
mediating some inflammatory processes (see for review 
[l]). In fact, injection of PLAzs into animals has been 
shown to induce some inflammatory responses [2,3]. 
Furthermore, two well-known inflammatory media- 
tors, IL-l [4-71 and TNF [7], have been found to release 
PLAz activity from human synovial cells and rabbit and 
rat chondrocytes. However, the mechanism of the 
elevation of extracellular PLAz activity and the type of 
PLA2 released from the cells have not been clarified yet. 
PLAzs characterized so far can be classified into two 
groups, based on their primary structures [8]. Mam- 
malian group I PLAzs exist mainly and abundantly in 
the pancreas [9-l 11. On the other hand, mammalian 
group II PLAzs have been found in rabbit ascites (121, 
rat peritoneal exudate [131, human rheumatoid arthritic 
synovial fluid [ 14-161, platelets of rabbit [ 171 and rat 
[ 18,191, porcine intestine [20], and rat spleen [21,22]. In 
this study using rat cultured aortic SMCs, we 
demonstrated for the first time that there are at least 
two distinct mechanisms in the activation of group II 
PLA2 gene expression: one is mediated by inflam- 
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matory l~pho~nes (IL-l and TNF) as well as LPS, 
and the other by cAMP-elevating agents. 
2. MATERIALS AND METHODS 
2.1. ~solat~on and cul~~vu~~o~ of smooth muscle ceils 
Rat thoracic aortic SMCs were isolated by enzymatic digestion of 
media of thoracic aorta from male Sprague-Dawley rats as described 
by Charnley-Campbell et al. [23]. The cells were cultured in DMEM 
containing 20% fetal calf serum. 
2.2. Activation of SMCs 
Confluent SMCs in 9~mm~ameter dishes were washed twice with 
DMEM and incubated with 8 ml of DMEM containing 0.1 mg/ml 
bovine serum albumin with or without the agents. At the end of in- 
cubation, the supernatant was removed for use in the PLAz assay and 
Western blotting. 
2.3. PLA2 assay 
Phospholip~e activity was measured by the hy~olysis of [“Cloleic 
acid (Amersham)-Iabeled ~c~eric~ia coli phospholipids [24]. The 
assay mixture contained 100 mM Tris, pH 7.4, and 1 mM CaCl2. The 
medium of the culture was diluted to produce hydrolysis of up to 10% 
of the substrate. Reaction mixtures were incubated for 1 h at 37”C, 
and the released [‘4C]oleic acid was extracted and measured as 
described elsewhere [24]. 
2.4. Western blotting 
Rabbit anti-rat group II PLAz IgG was produced against PLA2 
released from thrombin-stimulated rat platelets, which was purified 
as previously described [25]. Immunoblotting with the anti-rat group 
II PLAl IgG was accomplished after SDS gel electrophoresis using a 
blotting detection kit (Amersham). 
2.5. CAMP assay 
After the incubation of SMCs. CAMP was extracted with 15% 
trichloroacetic acid from the cells. CAMP was measured with a CAMP 
assay system (Amersham). 
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2.6. RNA blotting 
Total cellular RNA was prepared by the method of Chomoczynski 
and Sacchi [26]. The RNA was fractionated on a 1 olo agarose gel con- 
taining 2.2 M formaldehyde and transferred onto a nylon membrane 
by a standard method [27]. After immobilization of RNA by baking 
and UV cross-linking, hybridization was performed as described by 
Church and Gilbert [28]. Rat group II PLAz cDNA was labeled with 
[3ZP-(r]dCTP (New England Nuclear, 5000 Ci/mmol) using a random 
primer labeling system (Amersham), and used as a probe. After 
hybridization, the membrane was washed with 15 mM sodium 
citrate/l 5 mM NaCl/O. 1% SDS at 65“C several times. 
2.7. Materials 
Human recombinant TNF and human recombinant IL-l@ were 
purchased from Genzyme. LPS from E. coli was obtained from Pasel. 
Other chemicals were from Sigma. 
3. RESULTS AND DISCUSSION 
As reported for chondrocytes and synovial cells 
[4-71, IL-l and TNF greatly enhanced the release of 
PLA2 activity from SMCs (table 1). Moreover, we 
found that LPS also stimulated SMCs to secrete PLAz 
activity. To characterize this stimulation phenomenon 
further, we examined the effects of several agents on 
PLAz secretion from SMCs. The agents examined were 
as follows: forskolin, which stimulates adenylate 
cyclase; IBMX, which inhibits CAMP phosphodies- 
terase; dibutyryl CAMP, which is a membrane-per- 
meable CAMP analogue; dibutyryl cGMP, which is a 
membrane-permeable cGMP analogue; which activates 
protein kinase C. As illustrated in table 1, the agents 
which increase intracellular CAMP concentrations (for- 
skolin, IBMX and dibutyryl CAMP) enhanced the 
release of PLAz activity. On the other hand, dibutyryl 
cGMP and PMA had no effect on the secretion of 
PLA2. The stimulation of PLA2 secretion by forskolin 
or TNF was completely blocked by actinomycin D, an 
inhibitor of transcription, indicating that de novo RNA 
synthesis was necessary for enhancing the release of 
PLA2. 
Table 1 
Phospholipase activity in the culture medium of SMCs incubated with 
various stimuli for 24 h 
Addition Phospholipase activity 
IL-l (10 U/ml) 12.6 
TNF (1000 U/ml) 37.3 
LPS (100 ng/ml) 33.4 
Forskolin (10 PM) 17.3 
IBMX (0.5 mM) 7.5 
Dibutyryl CAMP (1 mM) 14.9 
Dibutyryl cGMP (1 mM) 1.6 
PMA (100 nM) 1.2 
Forskolin (10 pM plus 
actinomycin D (1 PM) 0.8 
TNF (1000 U/ml) plus 
actinomycin D (1 PM) 1.1 
Control 1.0 
Phospholipase activity is expressed as the relative change compared to 
the control sample. Data are the mean values from a representative 
experiment carried out in duplicate. 
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Fig.1. Elevation of group II PLA2 mRNA levels in SMCs incubated 
with various stimuli. SMCs were incubated with vehicle (a), 10 pM 
forskolin plus 1 CM actinomycin D (b), 10 PM forskolin (c), 0.5 mM 
IBMX (d), 1 mM dibutyryl CAMP (e), 1 mM dibutyryl cGMP (f), 100 
nM PMA (g), 1000 U/ml TNF (h) and 10 U/ml IL-l (i) for 24 h. Total 
cellular RNA (15 pg/lane) was analyzed with RNA blotting as describ- 
ed in section 2. 
To determine whether the stimulation of PLA2 secre- 
tion occurred at the mRNA level, we performed RNA 
blot analyses. As shown in fig. 1, levels of rat group II 
PLA2 mRNA increased upon stimulation with IL-l, 
TNF, forskolin, IBMX, and dibutyryl CAMP. Ac- 
tinomycin D inhibited the increase in the amount of 
PLAz mRNA, confirming that the elevation of PLA2 
mRNA level is a prerequisite to the stimulation of PLA2 
release. Since rat group I PLA2 mRNA could not be 
detected in all cases (data not shown), the released 
PLA2 from SMCs upon stimulation is a group II en- 
zyme. Protein blotting analysis using anti-rat group II 
PLA2 also showed that SMCs released group II PLA2s 
in response to stimulations (fig.3). 
The results described above suggest hat CAMP acted 
as a second messenger for the stimulation of group II 
PLAz gene expression. In the forskolin-treated cells, 
intracellular CAMP concentrations transiently increas- 
ed and remained much higher than in untreated cells 
even after 6 h of the incubation, as shown in fig.2. IL-l, 
TNF and LPS, however, did not change CAMP concen- 
trations in SMCs, suggesting that the signal transduc- 
tion mechanism evoked by these factors would be dif- 
ferent from that involving CAMP. In order to elucidate 
whether TNF stimulation was mediated by a different 
mechanism (e.g. a different trans-acting factor) from 
that in CAMP stimulation, we examined the effect of 
addition of forskolin on the TNF stimulation. If for- 
skolin and TNF stimulate the gene expression via the 
same mechanism, the output induced by forskolin plus 
TNF should not exceed the addition of the output in- 
duced by forskolin and TNF individually. However, as 
illustrated in table 2, the released PLA2 activity induced 
by forskolin plus TNF was far above the sum of the in- 
dividual effects. Forskolin (10 PM) increased the TNF- 
induced PLA2 activity about ten times at all the concen- 
trations of TNF. The synergistic effect of forskolin and 
TNF was also observed with Western blotting and Nor- 
thern blotting (fig.3). IL-I and LPS gave the same 
results as TNF (data not shown). These results indicated 
that IL-l-, TNF- and LPS-induced increases in the 
PLA2 gene transcript were mediated by a different 
mechanism from that stimulated by the CAMP- 
elevating agents, and the two mechanisms acted 
synergistically to stimulate the mRNA synthesis. 
Volume 261, number 1 FEBS LETTERS February 1990 
0 60 120 301 3 
Time (min) 
L 
Fig.2. CAMP in the SMCs treated with 10 PM forskolin (O), 10 U/ml 
IL-1 (A), 1000 U/ml TNF (A), 100 ng/ml LPS (V) or vehicle (0). 
Data are mean values of triplicate experiments. 
Recently, a study using human PLA2 cDNA as a pro- 
be has shown that IL-l stimulates PLA2 mRNA syn- 
thesis in rabbit chondrocytes, although the specificity 
of the probe was not indicated [29]. In the present 
study, we clarified for the first time that the inflam- 
matory mediators IL-l and TNF, as well as bacterial 
LPS, stimulated the gene expression and secretion of 
group II PLA2s but the rise in group I PLAz mRNA was 
not stimulated, by the use of rat group II PLA2 cDNA 
and anti-group II PLA2 IgG. Mammalian group II 
PLAzs are found in some inflammatory regions [12-161 
and have been shown to induce inflammatory responses 
[3]. These findings suggest he importance of the ex- 
tracellular release of group II PLAz in promoting in- 
flammatory processes. 
Our findings suggest hat group II PLA2 plays an im- 
portant role in the pathogenesis of vascular inflam- 
matory processes uch as vasculitis and atherosclerosis 
as well as the syndrome of septic shock. Recently, 
Pfeilschifter et al. also reported the release of PLA2 ac- 
tivity from vascular SMCs [30]. IL-l and TNF are pro- 
duced by macrophages and endothelial cells, and LPS 
may be derived from infecting bacteria. Furthermore, 
the dramatic potentiation of the effects of IL-l, TNF 
and LPS by CAMP-elevating agents raises the possibili- 
ty that some extracellular mediators which elevate the 
Table 2 
Phospholipase activity in the culture medium of SMCs incubated with 
TNF or TNF plus forskolin for 24 h 
TNF (U/ml) Phospholipase activity 
Without forskolin With 10 pM forskolin 
0 1.0 6.3 
1 1.3 9.8 
10 3.1 43.2 
100 9.6 115.7 
1000 19.2 185.5 
Phospholipase activity is expressed as the relative change compared to 
the control sample. Data are the mean values from a representative 
experiment carried out in duplicate. 
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Fig.3. The synergistic effect of forskolin and TNF on the release of 
group II PLAzs and the elevation of group II PLAz mRNA levels. 
SMCs were incubated with vehicle (a), 10 PM forskolin (b), 1000 
U/ml TNF (c) or 10 PM forskolin plus 1000 U/ml TNF (d). The 
culture medium of the cells or total cellular RNA (15 pg/lane) was 
analyzed with Western blotting (A) or RNA blotting (B) as described 
in section 2. 
intracellular CAMP level have a role in the progress of 
the above diseases by the combination with IL-l, TNF 
and LPS. In vascular systems, endothelial cells, SMCs 
and macrophages produce prostaglandins Ez and 12, 
which elevate the CAMP level in SMCs [31]. Such pro- 
stanoids may also have some roles in the progress of in- 
flammation in addition to the regulation of contraction 
of vascular smooth muscle. 
We are now studying the molecular mechanism of the 
regulation on group II PLA2 gene transcription as well 
as the physiological role of PLA2 in the progression of 
vascular inflammatory diseases. 
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